Exosens Shares Drop 4.08% to €57.60, Entering Oversold Territory
Exosens stock fell by 4.08% to €57.60 at midday this Monday, within an SBF 120 that dropped by 0.82% to 6,115.66 points. The specialist in night vision and imaging technologies for defense is among the top 5 biggest losers in the index. The decline intensifies even as the stock still maintains a 65% gain over the year.
Today's movement pushes Exosens below the lower boundary of its Bollinger Bands, set at €60.55. This configuration signals a potential oversold condition, with the price now about 5% below this lower limit. An RSI at 39 confirms selling pressure without reaching the classic oversold zone. The stock is significantly below its 20-day and 50-day moving averages, located at €64.19 and €64.55 respectively, with a gap of more than 10% for each. The 200-day average, at €51.04, remains 12.85% below the price, indicating that the long-term trend is not compromised. The technical support is at €57.50, a level at which the stock is currently trading. The resistance of €67.10 is moving away mechanically.
Tight Valuation Ahead of the General Meeting
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Based on analyst consensus, the stock is trading at about 30.6 times the expected earnings for the current fiscal year and 25.9 times those of the following year, with an estimated earnings per share growth of 18.4% between the two periods. These multiples compare to an industry average of around 18.4 times. The stock market sequence remains heavy after last week's decline, when the stock had dropped below €60 on Friday. As a reminder, the company reported a 19.7% increase in revenue to €122.6 million for the first quarter of 2026, announced on April 29. The next key event on the calendar is the annual general meeting scheduled for May 22, 2026, followed by the semi-annual results on July 28.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
